South San Francisco, CA May 10, 2017 Genentech Press Release — IMvigor211 study did not meet its primary endpoint of overall survival (OS) compared to chemotherapy — –The safety profile was consistent with what has been previously observed for TECENTRIQ–…
Tag: bladder cancer
FDA Grants Genentech’s Tecentriq (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer
South San Francisco, CA April 17, 2017 Press Release Genentech First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy — SOUTH SAN FRANCISCO, CA —…